Elan Frova Migraine Launch To Follow Finalized Co-Marketing Agreement
Executive Summary
Elan's Frova acute migraine therapy launch awaits finalization of a co-marketing agreement, which is expected to take place by year-end
You may also be interested in...
Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg
Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg
Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg
Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg
UCB to comarket Elan Frova
UCB will contribute 475 primary care sales reps to comarket Elan migraine therapy Frova (frovatriptan) under agreement announced March 28. Companies plan for second quarter 2002 launch. Neurologists will be detailed with Elan and UCB combined sales force of 265 reps under seven-year agreement. Frova was approved Nov. 8 (1"The Pink Sheet" Nov. 12, 2001, p. 35)...